MingMed Biotechnology
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biotech developing fully human antibody therapeutics for oncology and immunology.
OncologyImmunology
Technology Platform
Proprietary platform for the discovery and engineering of fully human monoclonal antibodies, enabling rapid generation of candidates against diverse targets.
Opportunities
Significant market opportunity in China for novel, differentiated immuno-oncology therapies with improved efficacy or safety profiles.
Risk Factors
Clinical and regulatory risks associated with novel mechanisms, alongside potential pricing pressure in the Chinese oncology market.
Competitive Landscape
Faces intense competition in the immuno-oncology space from both large multinationals and a crowded field of Chinese biotechs developing similar checkpoint inhibitors.